Literature DB >> 15841190

Benzodiazepines: Revisiting Clinical Issues in Treating Anxiety Disorders.

.   

Abstract

This AcademicHighlights section of The Primary Care Companion to The Journal of Clinical Psychiatry presents the highlights of the meeting "Utilizing Benzodiazepines in Clinical Practice: An Evidence-Based Discussion" held August 16, 2004, in Boston, Mass., and supported by an unrestricted educational grant from Pfizer Inc. This report was prepared by the CME Institute of Physicians Postgraduate Press, Inc.Chair Jerrold F. Rosenbaum, M.D., began the meeting by explaining that he had been asked to be a discussant at a case conference at Massachusetts General Hospital where Samantha A. Stewart, M.D., presented the case of a woman (described herein by Dr. Stewart) who was admitted with cognitive deficits potentially caused by benzodiazepine abuse and dependence--issues that were heavily debated during the 1980s. Dr. Rosenbaum stated that the purpose of the meeting was to address concerns related to benzodiazepine use in clinical practice today.

Entities:  

Year:  2005        PMID: 15841190      PMCID: PMC1076447     

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  38 in total

1.  An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder.

Authors:  M W Otto; K S Tuby; R A Gould; R Y McLean; M H Pollack
Journal:  Am J Psychiatry       Date:  2001-12       Impact factor: 18.112

Review 2.  Circuits and systems in stress. I. Preclinical studies.

Authors:  Eric Vermetten; J Douglas Bremner
Journal:  Depress Anxiety       Date:  2002       Impact factor: 6.505

3.  Long-term benzodiazepine therapy does not result in brain abnormalities.

Authors:  U E Busto; K E Bremner; K Knight; K terBrugge; E M Sellers
Journal:  J Clin Psychopharmacol       Date:  2000-02       Impact factor: 3.153

4.  Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study.

Authors:  L M Nagy; J H Krystal; S W Woods; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

5.  Acute effects of low-dose flumazenil in panic disorder.

Authors:  R J Maddock
Journal:  J Clin Psychopharmacol       Date:  1998-06       Impact factor: 3.153

6.  Lorazepam vs. alprazolam in the treatment of panic disorder.

Authors:  E Schweizer; R Pohl; R Balon; I Fox; K Rickels; V K Yeragani
Journal:  Pharmacopsychiatry       Date:  1990-03       Impact factor: 5.788

7.  Suicidality in panic disorder: a comparison with schizophrenic, depressed, and other anxiety disorder outpatients.

Authors:  S Friedman; L Smith; A Fogel
Journal:  J Anxiety Disord       Date:  1999 Sep-Oct

8.  Changes in caffeine states enhance return of fear in spider phobia.

Authors:  Jayson L Mystkowski; Susan Mineka; Laura L Vernon; Richard E Zinbarg
Journal:  J Consult Clin Psychol       Date:  2003-04

9.  Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder.

Authors:  M W Otto; M H Pollack; G S Sachs; S R Reiter; S Meltzer-Brody; J F Rosenbaum
Journal:  Am J Psychiatry       Date:  1993-10       Impact factor: 18.112

10.  Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder.

Authors:  G E Tesar; J F Rosenbaum; M H Pollack; M W Otto; G S Sachs; J B Herman; L S Cohen; S A Spier
Journal:  J Clin Psychiatry       Date:  1991-02       Impact factor: 4.384

View more
  1 in total

1.  The Therapeutic Effects of Low-Frequency Electrical Stimulations Adjunct to Sodium Valproate on Seizure and Behaviors.

Authors:  Raha Zalkhani; Ahmad Ali Moazedi; Zohreh Ghotbeddin; Mahdi Pourmahdi Borujeni
Journal:  Basic Clin Neurosci       Date:  2020-01-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.